Management of metastatic breast cancer with second-generation antibody-drug conjugates: focus on glembatumumab vedotin (CDX-011, CR011-vcMMAE). (Q38185304)

From Wikidata

Jump to navigation Jump to search

scientific article published on June 2014

Language	Label	Description	Also known as
English	Management of metastatic breast cancer with second-generation antibody-drug conjugates: focus on glembatumumab vedotin (CDX-011, CR011-vcMMAE).	scientific article published on June 2014

Statements

scholarly article

1 reference

Europe PubMed Central

30 August 2017

Management of metastatic breast cancer with second-generation antibody-drug conjugates: focus on glembatumumab vedotin (CDX-011, CR011-vcMMAE). (English)

1 reference

Europe PubMed Central

30 August 2017

metastatic breast cancer

1 reference

based on heuristic

inferred from title

author name string

Christos Vaklavas

1

1 reference

Europe PubMed Central

30 August 2017

Andres Forero

2

1 reference

Europe PubMed Central

30 August 2017

publication date

1 June 2014

1 reference

Europe PubMed Central

30 August 2017

1 reference

Europe PubMed Central

30 August 2017

28

1 reference

Europe PubMed Central

30 August 2017

3

1 reference

Europe PubMed Central

30 August 2017

253-263

1 reference

Europe PubMed Central

30 August 2017

https://scigraph.springernature.com/pub.10.1007/s40259-014-0085-2

0 references

Trastuzumab emtansine for HER2-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

Antibody conjugate therapeutics: challenges and potential

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

ADAM10 releases a soluble form of the GPNMB/Osteoactivin extracellular domain with angiogenic properties

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

Osteoactivin promotes breast cancer metastasis to bone

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

Seven novel and stable translocations associated with oncogenic gene expression in malignant melanoma.

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

DC-HIL/glycoprotein Nmb promotes growth of melanoma in mice by inhibiting the activation of tumor-reactive T cells

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

Osteoactivin expressed during cirrhosis development in rats fed a choline-deficient, l-amino acid-defined diet, accelerates motility of hepatoma cells

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

Identifying potential tumor markers and antigens by database mining and rapid expression screening

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

Bone-related genes expressed in advanced malignancies induce invasion and metastasis in a genetically defined human cancer model.

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index.

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

Construction of engineered CHO strains for high-level production of recombinant proteins

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

nmb, a novel gene, is expressed in low-metastatic human melanoma cell lines and xenografts

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

Glycoprotein nonmetastatic melanoma protein b, a melanocytic cell marker, is a melanosome-specific and proteolytically released protein

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

DC-HIL is a negative regulator of T lymphocyte activation

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

Gpnmb is a melanosome-associated glycoprotein that contributes to melanocyte/keratinocyte adhesion in a RGD-dependent fashion

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

Molecular cloning of a dendritic cell-associated transmembrane protein, DC-HIL, that promotes RGD-dependent adhesion of endothelial cells through recognition of heparan sulfate proteoglycans

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

Osteoactivin is a novel osteoclastic protein and plays a key role in osteoclast differentiation and activity

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

Osteoactivin acts as downstream mediator of BMP-2 effects on osteoblast function

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

Osteoactivin, an anabolic factor that regulates osteoblast differentiation and function

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

Microphthalmia transcription factor regulates the expression of the novel osteoclast factor GPNMB.

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

Gpnmb is induced in macrophages by IFN-gamma and lipopolysaccharide and acts as a feedback regulator of proinflammatory responses

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

The DC-HIL/syndecan-4 pathway inhibits human allogeneic T-cell responses

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL.

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

CD20-specific antibody-targeted chemotherapy of non-Hodgkin’s B-cell lymphoma using calicheamicin-conjugated rituximab

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0085-2

21 January 2018

Identifiers

10.1007/S40259-014-0085-2

1 reference

Europe PubMed Central

30 August 2017

1 reference

Europe PubMed Central

30 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38185304&oldid=2099831316"